Navigation Links
Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Date:8/19/2007

Levodopa Remains the Most Widely Prescribed Drug for Parkinson's Disease,

According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 61 percent of newly diagnosed Parkinson's disease patients do not receive any drug treatment in the first year of diagnosis. According to the new report entitled Treatment Algorithms for Parkinson's Disease, failure of newly diagnosed Parkinson's disease patients to receive pharmacological treatment within the first 12 months of diagnosis likely occurs as a result of patients' decisions to delay treatment until symptoms become sufficiently troublesome. Furthermore, because the guidelines of the American Academy of Neurology (AAN) do not define specific time periods for when treatment should be initiated, patients may be reluctant to begin levodopa therapy, such as with Bristol Myers Squibb's Sinemet, knowing that side-effects will arise, specifically motor response complications.

Levodopa provides greater motor benefit than dopamine agonists, such as GlaxoSmithKline's Requip or Boehringer Ingelheim's Mirapex, but inevitably results in the development of levopoda-induced side effects, including dyskinesias, off time (sudden motor switches between normal and Parkinson movements) and wearing-off complications (shortened periods of benefit after each levodopa use).

"Levodopa continues to be the gold-standard Parkinson's disease treatment, with 99% of neurologists and 95% of PCPs we surveyed currently prescribing it in their Parkinson's disease practice," said Nicole Westphal, Ph.D., analyst at Decision Resources. "However, first-line levodopa use will decrease over the next two years as physicians increasingly use levodopa-sparing approaches. Patient demand for well-tolerated, levodopa-sparing treatments will continue to drive increases i
'/>"/>

SOURCE Decision Resources

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
6. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
7. Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers
8. Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance
9. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
10. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
11. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sony Biotechnology Inc. ("Sony") today announced the launch of the ... chip.  Sony will also be exhibiting its newly rebranded reagent ... the EC800 flow cytometer, and new SP6800 Spectral Analyzer will ... be held at the San Diego ... from May 20 - 22.  The 8-well ...
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
(Date:5/17/2013)... LAKES, Fla. , May 17, 2013 Fuse ... and delivery technology company that is developing new, patent-pending technologies ... minerals, announced today that it will hold a business update ... Wednesday, May 22 nd , 2013 at 4:30 PM ET. ... Tuffin will host the call and will be ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
... -- China Health Resource, Inc. (OTCBB: CHRI), today announced results ... the first quarter of 2012. Revenues for ... increase of 234% over revenues of US $10,282,207 for 2010. For ... common share, compared with a net income of $2,707,286, or ...
... Oncos Therapeutics today announced the successful initiation ... adenovirus suggested as a potential new treatment for many types ... safety assessment part of the study. " We ... r thern Europe to start a clinical study with ...
Cached Medicine Technology:China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012 2China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012 3Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 TheBeautyPlace.com answers ... Pattern hair loss is not a result of stress, ... to Men’s Fitness Magazine, 70% of men suffer from ... Strength is renowned for hair transplant surgery, but ... male pattern baldness known as Bosley Professional Strength. Their ...
(Date:5/18/2013)... Family Magazine of Washington DC was awarded the "Best ... Inc. in the category of Summer Camps in DC ... the areas best in the ultimate guide on parenting, kids ... Brenda Hyde, a mother of four and publisher of Family ... vast resources available to them in the DC Metro area. ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... mount in courts throughout the country, Bernstein Liebhard LLP ... hip replacement patients often suffer tissue damage before they ... study, which according to Science Daily will appear in ... hip replacement recipients underwent MRI screens of their hips. ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... 29, 2009) The allergen breathed in by a person ... activates a cascade of events to prompt an allergic reaction, ... Medicine ( www.bcm.edu ) in Houston in a report that ... , In particular, MMP7 activates interleukin 25, a key mediator ...
... shortness of breath and trimmed hospital stays, phase 2 study ... relaxin reduces shortness of breath and cardiovascular death in people ... to a phase 2 trial conducted in eight countries. ... hours of arriving at a hospital, were randomly assigned to ...
... to clean equipment regularly with alcohol wipes , , ... three stethoscopes used by U.S. emergency medical service ... bacteria, a new study suggests. , Researchers at ... Jersey swabbed 50 stethoscopes used by independent emergency ...
... recently reported on new Baxter Heparin testing standards that are to ... following several deaths after the contaminated drug was used on patients, ... an ingredient that caused the deaths of several and sickened hundreds. ... ...
... M.D., MPH, co-director of the National Center for Vermiculite ... Cancer Institute in Detroit, MI, and chief of the ... University , announced the use of a new technology ... The announcement was made at the Asbestos Disease Awareness ...
... In what has quickly evolved into a historic ... in Northwestern Minnesota and Eastern North Dakota, is ... the region. Despite rising flood waters and disrupted ... are still accepting patients, according to officials. To ...
Cached Medicine News:Health News:Hormone Reduces Mortality in Heart Patients With High BP 2Health News:Third of EMS Stethoscopes Carry MRSA Bacterium 2Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 2Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 3Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 4Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 3Health News:Innovis Health Continues to Serve Region 2
Provides a combination of concentrated cold / hot and compression for the neck...
Provides a combination of concentrated cold / hot and compression for the back...
... One-Piece™ Collar is completely injected molded from ... our patented chin support. , ,Our ... efficiently managed where space is limited. Color-coded ... of sizes., ,Either in a supine ...
... optional hot and cold therapy Gel Pad. Our ... providing cold therapy to reduce swelling and /or ... recovery., ,To order hot and cold therapy ... number., ,Our suspenders can be added to ...
Medicine Products: